News

Video

How Do You Explain Neoadjuvant Therapy in NSCLC?

Related Videos
2 experts are featured in this series.
2 experts are featured in this series.
Gustavo Werutsky, MD, PhD, medical oncologist, Breast Cancer Program, Hospital Moinhos de Vento; investigator, Oncology Research Centre, Hospital São Lucas PUCRS University
Ewa Kalinka, MD, PhD
3 experts are featured in this series.
Rohan Garje, MD
Aparna Parikh, MD, medical oncologist, Massachusetts General Hospital
Tycel J. Phillips, MD, MPH
Related Content
Anna Bianchi-Smiraglia, PhD
January 20th 2025

Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer

Oncology PER® Spectives™: Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations
January 16th 2025

Oncology PER® Spectives™: Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

FDA Grants Orphan Drug Designation to ELC-100 for Pancreatic NETs | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 20th 2025

FDA Grants Orphan Drug Designation to ELC-100 for Pancreatic NETs

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
January 15th 2025

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma | Image Credit: © MdBabul - stock.adobe.com
January 18th 2025

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma